Because it's rare and not always top of mind for doctors, TED can quietly progress or be mistaken for allergies or Graves' ...

By Siddhi Mahatole May 5 (Reuters) - Viridian Therapeutics said on Tuesday its experimental thyroid eye disease drug met the ...

Whereas earlier Phase 3 results disappointed Wall Street, new findings in people with “chronic” disease were viewed by ...

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...

New research suggests that progression of thyroid eye disease is not limited to the early disease period, with a number of ...

The most useful biomarker for extraocular muscle enlargement in thyroid eye disease (TED) is unclear. According to this study, higher thyroid-stimulating antibody (TSAb) levels and older age were ...

Thyroid eye disease (TED), also known as Graves’ eye disease, usually stems from an autoimmune condition that starts when immune cells attack the thyroid gland, a tiny butterfly-shaped gland at the ...

Madhura Tamhankar, MD, took some time at the ARVO conference in Denver, Colorado, to discuss disease progression in thyroid ...

An injectable monoclonal antibody that targets the insulin-like growth factor I receptor improved proptosis in more than half ...

Viridian Therapeutics' shares rose after the company said its treatment for thyroid eye disease met its primary endpoint in a recent trial. The stock gained 58% to $22.30 in premarket trading Tuesday.

BOSTON—Most patients with thyroid eye disease treated with teprotumumab didn’t require additional treatments nearly 2 years later, according to industry-supported research being presented Sunday at ...

“In our study, Black patients with TED presented with fewer clinical exam features based on current classification guidelines, but had longer follow-up and underwent similar treatments as White ...